Jun 15, 2026 07:02AM
May 5, 2026 04:20AM
May 4, 2026 01:15PM
Apr 1, 2026 05:41PM
Apr 1, 2026 12:10PM
Feb 24, 2026 05:40AM
Feb 23, 2026 12:32PM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Feb 2, 2026 09:00AM
Jan 20, 2026 06:39AM
Jan 13, 2026 04:52AM
Jan 2, 2026 08:53AM
Dec 31, 2025 01:54PM
Dec 31, 2025 01:19PM
Dec 31, 2025 12:42PM Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer
Dec 31, 2025 08:25AM
Dec 31, 2025 08:24AM
Dec 31, 2025 06:55AM
Nov 6, 2025 07:01AM
Jul 22, 2025 07:28AM
Jul 22, 2025 06:38AM
Jul 18, 2025 09:58AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Jun 10, 2025 09:24AM
Jun 10, 2025 06:39AM
Jun 9, 2025 11:54AM
Jun 9, 2025 07:02AM
Apr 7, 2025 02:31AM
Apr 4, 2025 07:00AM
Jan 21, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jan 13, 2025 12:50PM
Nov 26, 2024 07:00AM
Sep 16, 2024 08:43AM
Mar 28, 2024 06:29AM
Mar 26, 2024 07:23AM
Mar 25, 2024 06:31AM
Mar 19, 2024 03:34AM Baird Starts Axsome Therapeutics (AXSM) at Outperform, 'we anticipate the sales trajectory will remain strong'
Jan 4, 2024 07:04AM
Nov 1, 2022 05:34AM
Apr 19, 2022 09:24AM
Jun 15, 2021 07:01AM
Sep 21, 2020 07:04AM
Aug 5, 2020 07:18AM
Jan 13, 2020 06:05AM Axsome Therapeutics (AXSM) Announces Exclusive License Agreement for Pfizer’s (PFE) Reboxetine Clinical/Nonclinical Data &New Ph. 3 Esreboxetine Product Candidate
Dec 17, 2019 09:19AM
Dec 3, 2019 09:16AM
Dec 3, 2019 06:05AM
Oct 21, 2019 07:02AM
Oct 2, 2019 08:47AM
Jan 30, 2019 07:00AM
Dec 27, 2018 07:01AM Axsome Therapeutics (AXSM) Reports Year End 2018 Clinical Update
Oct 17, 2018 09:37AM

67,159 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All